Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Bevacizumab in EGFR+ Non-Squamous NSCLC
NCT04426825Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Objective Response Rate at 10 months. Started Sep 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04426825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04426825.